BiotechTube
CordenPharma

CordenPharma

Lyon, France· Est.
cordenpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

CordenPharma is a full-service, global CDMO offering end-to-end development and manufacturing services for complex drug substances and products. Founded in 2006, it has established itself as a key partner in advanced therapeutic areas, leveraging specialized technology platforms in peptides, oligonucleotides, lipids/LNPs, injectables, and highly potent small molecules. The company focuses on providing integrated, scalable solutions from clinical development through commercialization, emphasizing quality, supply chain security, and scientific partnership. Its business model is entirely service-based, generating revenue through contracts with pharmaceutical and biotechnology companies.

Small MoleculesBiologicsDrug Delivery

Technology Platform

Integrated CDMO platforms for Peptides (TAPS), Oligonucleotides, Lipids & LNPs, Injectables, Highly Potent & Oncology, and Small Molecules, with support services in flow chemistry, crystallization, and purification.

Funding History

1
Total raised:$150M
Debt$150M

Opportunities

Explosive growth in mRNA and gene therapy markets drives high demand for its lipid excipient and LNP manufacturing services.
The trend towards outsourcing by biopharma companies, especially for complex modalities, expands its potential client base.
Offering integrated, end-to-end services from API to drug product allows it to capture more value per client program.

Risk Factors

Operational risks include quality control failures or supply chain disruptions at its GMP facilities, which could damage client relationships.
Intense competition from larger, public CDMOs and niche specialists could pressure pricing and market share.
Dependency on the continued investment and strategic direction of its private equity owner, ICIG.

Competitive Landscape

CordenPharma competes in a fragmented but competitive global CDMO market. It faces large, full-service competitors like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized peers in peptides (e.g., Bachem), oligonucleotides, and lipids (e.g., Evonik, Merck). Its differentiation lies in its integrated service offering across key advanced modalities and its focus on complex, potent compounds.

More companies in Biologics / Biosimilars →More companies in France →